PRESS RELEASE 2014

• Ferring Pharmaceuticals Announces Grand Opening of U.S. Operations Center

Ferring Pharmaceuticals has expanded its footprint in New Jersey with the opening of its new U.S. Operations Center on a 25-acre lot located at 100…

• New data from a pooled analysis shows improved overall survival for prostate cancer patients treated with FIRMAGON® (degarelix) compared to LHRH agonists

New data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS)…

• CORTIMENT®MMX®, a new treatment for ulcerative colitis, receives European approval

Ferring Pharmaceuticals announced today that its CORTIMENT® MMX® (budesonide) treatment for the induction of remission in patients…

• The Scottish Medicines Consortium (SMC) accepts MYSODELLE® for use in NHS Scotland

Ferring Pharmaceuticals Ltd, U.K. announced today that the Scottish Medicines Consortium (SMC) has accepted its new product…

• Ferring Pharmaceuticals and Roche collaborate to develop personalised infertility treatment

Ferring Pharmaceuticals and Roche have announced a collaboration to combine diagnostic testing technology from Roche with Ferring’s human cell…

• Ferring launches Guts4life, an interactive online resource for people with inflammatory bowel disease

Ferring Pharmaceuticals marks World IBD Day (May 19th) with the launch of Guts4life (www.guts4life.com), a new interactive website with information…

• New study suggests desmopressin melt improves sleep patterns and psychological functioning of bedwetting children

New data has shown that treatment with melt-in-the-mouth desmopressin (MINIRIN® Melt)* improved sleep patterns and psychological functioning…

• Real-world patient survey data shows negative impact of nocturia

New patient survey data presented today at the European Association of Urology (EAU 14) congress, showed that nocturia…

• MSD, Ferring Pharmaceuticals and the World Health Organization – Working Together to Prevent Excessive Bleeding in Women after Childbirth

Ferring Pharmaceuticals and MSD, known as Merck in the United States and Canada, today announced their collaboration with the World Health…

• New paper indicates a potential fifty-percent reduction in cardiac events for prostate cancer patients with pre-existing cardiovascular disease when treated with FIRMAGON® (degarelix) compared to LHRH agonists

A paper published today in European Urology, the official journal of the European Association of Urology, indicates that the gonadotropin…